Published in Clin Sarcoma Res on December 18, 2013
Pulmonary extraskeletal myxoid chondrosarcoma: A case report and literature review. Int J Surg Case Rep (2016) 0.75
Unresectable Extraskeletal Myxoid Chondrosarcoma of the Neck: Early Tumor Response to Chemoradiotherapy. Cureus (2015) 0.75
Next generation sequencing of extraskeletal myxoid chondrosarcoma. Oncotarget (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am J Surg Pathol (2003) 3.30
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A (1997) 3.22
The clinical approach towards chondrosarcoma. Oncologist (2008) 3.01
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 2.45
Extraskeletal myxoid chondrosarcoma: a reappraisal of its morphologic spectrum and prognostic factors based on 117 cases. Am J Surg Pathol (1999) 2.13
Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. Cancer (1998) 1.56
Extraskeletal myxoid chondrosarcoma: a Multi-Institutional Study of 42 Cases in Japan. Cancer (2003) 1.53
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer (2008) 1.53
p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res (2003) 1.16
Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol (1995) 1.15
Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res (2001) 1.14
Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21). Cancer Res (2000) 1.14
The gene expression profile of extraskeletal myxoid chondrosarcoma. J Pathol (2005) 1.13
Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol (2013) 1.08
Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology (2001) 1.06
Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res (1999) 1.06
Translocation (9;22)(q22;q12). A recurrent chromosome abnormality in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet (1995) 1.04
Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer (1995) 1.04
Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up. Arch Orthop Trauma Surg (2012) 0.98
The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol (2009) 0.97
Myxoid chondrosarcoma with a translocation involving chromosomes 9 and 22. Cancer Genet Cytogenet (1985) 0.97
Extraskeletal myxoid chondrosarcoma: a case report of complete remission by chemotherapy and review of the literature. BMJ Case Rep (2010) 0.89
Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res (2012) 0.89
NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma. Virchows Arch (2012) 0.83
Osseous myxochondroid sarcoma: a detailed study of 5 cases of extraskeletal myxoid chondrosarcoma of the bone. Am J Surg Pathol (2013) 0.81
S-100 protein positive synovial sarcoma. Histopathology (1991) 0.79
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell (2007) 10.13
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol (2007) 5.50
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology (2004) 3.61
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med (2006) 3.11
Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2006) 2.98
Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer (2011) 2.95
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer (2005) 2.54
Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol (2009) 2.48
Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer (2004) 2.46
Myopericytoma of skin and soft tissues: clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol (2006) 2.46
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg (2007) 2.30
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev (2004) 2.20
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res (2005) 2.20
Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol (2005) 2.19
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer (2003) 2.11
Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res (2004) 1.99
Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol (2003) 1.99
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ (2005) 1.97
Imatinib mesylate in chordoma. Cancer (2004) 1.94
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol (2005) 1.94
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol (2010) 1.93
Phase II study of imatinib in advanced chordoma. J Clin Oncol (2012) 1.89
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene (2004) 1.82
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann Surg Oncol (2007) 1.76
Chordoma. Curr Opin Oncol (2007) 1.75
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer (2004) 1.65
PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. Am J Surg Pathol (2008) 1.65
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol (2011) 1.64
Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification. Genes Chromosomes Cancer (2010) 1.63
Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg (2010) 1.62
Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol (2005) 1.61
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol (2003) 1.61
Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer (2004) 1.61
A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg (2005) 1.60
Evaluation of ocular surface disorders: a new diagnostic tool based on impression cytology and confocal laser scanning microscopy. Br J Ophthalmol (2009) 1.59
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer (2012) 1.57
Long-term effectiveness of autologous cultured limbal stem cell grafts in patients with limbal stem cell deficiency due to chemical burns. Clin Experiment Ophthalmol (2011) 1.56
High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology (2009) 1.53
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther (2009) 1.52
Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol (2005) 1.51
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
Soft tissue tumors associated with EWSR1 translocation. Virchows Arch (2010) 1.50
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res (2012) 1.49
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol (2009) 1.48
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab (2007) 1.47
Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol (2007) 1.46
Translocation-related sarcomas. Semin Oncol (2009) 1.45
Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer (2005) 1.45
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem (2005) 1.44
Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res (2008) 1.43
Thoracopleuropneumonectomy with riblike reconstruction for recurrent thoracic sarcomas. Ann Surg Oncol (2014) 1.40